The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, and eczema.

The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, and eczema.

A soothing lip balm composition includes a wax binder component, which includes at least two compounds selected from a C.sub.8-C.sub.30 fatty acid, esterified C.sub.8-C.sub.30 fatty acid, and C.sub.8-C.sub.30 fatty alcohols; a complex fat component, which includes at least three different compounds selected from C.sub.8-C.sub.30 fatty acids; an organic compound component, which includes at least three compounds selected from 2,5-dimethoxy-p-cymene, cumene, thymol methyl ether, 2,6-diisopropylanisole, decanal, and 1,2,2,3-tetramethylcyclopent-3-enol; and an enzymatic component, which includes cysteine endopeptidase.

A soothing lip balm composition includes a wax binder component, which includes at least two compounds selected from a C.sub.8-C.sub.30 fatty acid, esterified C.sub.8-C.sub.30 fatty acid, and C.sub.8-C.sub.30 fatty alcohols; a complex fat component, which includes at least three different compounds selected from C.sub.8-C.sub.30 fatty acids; an organic compound component, which includes at least three compounds selected from 2,5-dimethoxy-p-cymene, cumene, thymol methyl ether, 2,6-diisopropylanisole, decanal, and 1,2,2,3-tetramethylcyclopent-3-enol; and an enzymatic component, which includes cysteine endopeptidase.

Food scent substance for use in the treatment of obesity, wherein food scent from the food scent substance is inhaled from a device comprising the food scent substance.

Food scent substance for use in the treatment of obesity, wherein food scent from the food scent substance is inhaled from a device comprising the food scent substance.

Self-nanoemulsifying drug delivery system (SNEDDS) composition are provided. The compositions include at least one chemotherapeutic compound or a pharmaceutically acceptable salt thereof or mixture thereof, at least one biocompatible surfactant, wherein the at least one biocompatible surfactant includes surfactin, and at least one co-surfactant. Methods of enhancing the bioavailability of the chemotherapeutic compound and for treating cancer are also provided.

Self-nanoemulsifying drug delivery system (SNEDDS) composition are provided. The compositions include at least one chemotherapeutic compound or a pharmaceutically acceptable salt thereof or mixture thereof, at least one biocompatible surfactant, wherein the at least one biocompatible surfactant includes surfactin, and at least one co-surfactant. Methods of enhancing the bioavailability of the chemotherapeutic compound and for treating cancer are also provided.

An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine—cation exchange resin complex—matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine—cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.

An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine—cation exchange resin complex—matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine—cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.